Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of f...
Main Authors: | F.A. Cadegiani, A. Goren, C.G. Wambier, J. McCoy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | New Microbes and New Infections |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297521000792 |
Similar Items
-
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
by: R. Choudhary, et al.
Published: (2020-05-01) -
Social Media and COVID-19—Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics
by: Bangalee, V., et al.
Published: (2022) -
Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
by: Filippo Albani, et al.
Published: (2020-08-01) -
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
by: Samia Arshad, et al.
Published: (2020-08-01) -
Hydroxychloroquine and azithromycin use in COVID-19 era and cardiovascular concerns: Current perspective
by: Aditya Kapoor, et al.
Published: (2021-01-01)